Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

No results are reported in this dataset abstract, which details supplementary materials for a systematic review and meta-analysis on oral Janus kinase inhibitors' effectiveness and safety in children with alopecia areata, aiming to enhance transparency and interpretation of the main article's findings.

This study found that trichoscopy aided in assessing treatment responses for patchy alopecia areata, with both intralesional corticosteroids and platelet-rich plasma showing effectiveness, but only PRP significantly improved patient symptom impact scores.

In a Belgian cohort study, nearly 90% of alopecia areata patients treated with oral baricitinib experienced hair regrowth, with more than 70% achieving a favorable SALT score, particularly in patchy cases, though some relapsed post-treatment. No serious adverse events were noted.

In this retrospective analysis, baricitinib 4 mg was found to improve hair regrowth and was deemed effective and safe for treating severe alopecia areata in a real-world setting.

In this study, researchers found that among patients with severe alopecia areata, a change in SALT scores of 42 or 43 points represents meaningful improvement, highlighting the need to consider individual treatment goals beyond conventional low SALT score targets when assessing treatment benefits.